REVB Stock Summary and Trading Ideas (Revelation Biosciences | NASDAQ:REVB)

Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.

Revelation Biosciences trades on the NASDAQ stock market under the symbol REVB.

As of October 26, 2026, REVB stock price declined to $3.54 with 11,505 million shares trading.

REVB has a beta of 2.21, meaning it tends to be more sensitive to market movements. REVB has a correlation of 0.10 to the broad based SPY ETF.

REVB has a market cap of $2.01 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, REVB traded as high as $33,949.44 and as low as $3.08.

REVB has underperformed the market in the last year with a price return of -89.6% while the SPY ETF gained +15.1%. REVB has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -52.8% and -33.5%, respectively, while the SPY returned +3.9% and -1.7%, respectively.

REVB support price is $3.51 and resistance is $4.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that REVB shares will trade within this expected range on the day.